108511-97-3

Usage

Uses

Used in Pharmaceutical Industry:
4-Aminoisoxazole is used as a key reactant in the design and synthesis of hydroxyethylene-based HIV-1 protease inhibitors. These inhibitors contain a heterocyclic P1''-P2'' amide bond isostere, which is crucial for their antiviral activity against HIV-1. 4-Aminoisoxazole's unique structure allows for the development of potent and selective inhibitors that can effectively combat the virus.
Additionally, 4-Aminoisoxazole is utilized in the development of pyrimidine derivatives that act as JAK3 inhibitors. JAK3 (Janus kinase 3) is a protein tyrosine kinase involved in the signaling pathways of various cytokines and growth factors. Inhibition of JAK3 has therapeutic potential in the treatment of autoimmune diseases and inflammatory conditions, as it can modulate the immune response and reduce inflammation.

Upstream product

• 847490-69-1 4-iodoisoxazole 
• 122686-14-0 N-(4-methoxyphenyl)-N'-(5-methylisoxazol-4-yl)thioharnstoff 
• 1121-13-7 4-nitroisoxazole 

Downstream Products

• 1190843-61-8 phenyl isoxazol-4-ylcarbamate 
• 149976-34-1 (2R,4S,5S)-2-benzyl-5-<(tert-butoxycarbonyl)amino>-4-(tert-butyldimethylsiloxy)-N-(isoxazol-4-yl)-6-phenylhexanamide 
• 1285515-76-5 2-{[(4-fluorophenyl)methyl]oxy}-N-4-isoxazolyl-5-(1-methyl-1H-pyrazol-4-yl)benzamide 
• 1285514-44-4 N-4-isoxazolyl-2-[(phenylmethyl)oxy]-5-(4-pyridinyl)benzamide 

Relevant academic research and scientific papers

On the intrinsic reactivity of highly potent trypanocidal cruzain inhibitors

The cysteine protease cruzipain is considered to be a validated target for therapeutic intervention in the treatment of Chagas disease. Hence, peptidomimetic cruzipain inhibitors having a reactive group (known as warhead) are subject to continuous studies

Generation of an 4-Isoxazolyl Anion Species: Facile Access to Multifunctionalized Isoxazoles

A direct functionalization of unsubstituted isoxazole (1) was achieved by generation of 4-isoxazolyl anion species (3). An efficient 4-iodination of isoxazole and halogen–metal exchange reaction using a turbo Grignard reagent (iPrMgCl? LiCl) were essentia

NOVEL COMPOUNDS

The present invention discloses novel compounds inhibiting LRRK2 kinase activity, the preparation processes thereof, the compositions containing them, as well as the use in treating diseases characterized by LRRK2 kinase activity, particularly Parkinson's disease and Alzheimer's disease.

65. Herstellung von substituierten 2-Aminooxazol-4-carbonitrilen.

During our synthetic programme to convert 4-isoxazolylthioureas 3 into the corresponding carbodiimides 5, a side reaction leading to the hitherto unknown 2-aminooxazole-4-carbonitriles 6 was observed.By selecting appropriate reaction conditions, it was po

Synthesis of 4(5)-Acyl-, 1-Substituted 5-Acyl, and 1-Substituted 4-Acyl-1H-imidazoles from 4-Aminoisoxazoles

4-Aminoisoxazoles can be acylated with a wide variety of activated carboxylic acids.Hydrogenation of the resulting amides gives α-(acylamino)enaminones, which cyclize to 4(5)-acylimidazoles upon treatment with base.This method allows for the synthesis of acylimidazoles with a wide range of substituents at C-2.Utilization of N-substituted 4-aminoisoxazoles in the same sequence of reactions yields 1-substituted 5-acylimidazoles, a substitution pattern not otherwise easily prepared.Treatment of α-(acylamino)enaminones, derived from N-unsubstituted isoxazoles, with primary amines leads to incorporation of the amine at the β-position with concomitant expulsion of ammonia.This sequence efficiently yields 1-substituted and 1,2-disubstituted 4-acylimidazoles but does not give satisfactory yields of 5-substituted 4-acylimidazoles due to steric inhibition of the amine exchange.